<DOC>
	<DOCNO>NCT02884544</DOCNO>
	<brief_summary>The phase 2 study evaluate safety , tolerability efficacy HLD100 steady state ( follow 5 week treatment ) child use outpatient , single-center , open-label , flexible dose-escalation study design .</brief_summary>
	<brief_title>A Study Delayed Extended Release Formulation Dextroamphetamine Sulfate ( HLD100 ) Children With Attention-Deficit/Hyperactivity Disorder</brief_title>
	<detailed_description>This dose-escalation study examine HLD100 24 subject . The subject ( n=24 ) test HLD100 ascend dos 10mg 40mg . This study divide several phase : Screening , Active Treatment Follow-Up . All visit 2 day window allow scheduling .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Dextroamphetamine</mesh_term>
	<criteria>Subjects must diagnosis ADHD define DSM5 criterion confirmation use Mini International Neuropsychiatric Interview Children Adolescents ( MINIKID ) . Subjects must demonstrate mildtomoderate impairment ADHD symptom function per follow screening ( V1 ) and/or baseline ( V2 ) : ADHDRSIV score 90th percentile normalize sex age total score ≥24 Baseline ; CGIS score ≥4 ; Subject body weight must ≥20 kg . Subject must consider clinically appropriate treatment amphetamine HLD100 , include prior treatment experience amphetamine product , ability swallow treatment capsule . History , current , medical condition laboratory result , opinion investigator , unfavorably alters riskbenefit study participation , may jeopardize subject safety , may interfere satisfactory completion study studyrelated procedure . Serious structural cardiac abnormality , cardiomyopathy , serious heart rhythm abnormality , cardiac problem may place subject increase vulnerability sympathomimetic effect stimulant drug . History seizure disorder ( except febrile seizure prior age 5 last occurrence least 1 year prior study participation ) , Tourette 's disorder , intellectual disability minor severity great ( DSM5 criterion ) . History psychosis , bipolar disorder , anorexia nervosa , bulimia , suicide attempt . Current depression , anxiety , conduct/behavior disorder , substance use disorder , psychiatric condition , investigator 's opinion , may jeopardize subject safety may interfere satisfactory completion study studyrelated procedure . Active suicidal ideation evidence ideation score 2 great CSSRS . History severe allergic reaction intolerance amphetamine .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>